Indian competition regulator clears Novartis-GSK transactions

The Competition Commission of India (CCI) has cleared Novartis and GlaxoSmithKline's multi-segment transactions in India and ruled out any input/customer ''foreclosure'' concerns as a result of the firms' combination in the area of vaccines.

The Competition Commission of India (CCI) has cleared Novartis and GlaxoSmithKline's multi-segment transactions in India and ruled out any input/customer ''foreclosure'' concerns as a result of the firms' combination in the area of vaccines.

The Indian deals are a result of a global transaction announced in April under which Novartis was to divest its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category